Health

STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 08/11/2026, 09:36:24 UTC.

Briefings

Two recent heart drug trials presented at the American Heart Association failed to show benefits despite genetic improvements, challenging AI hype claims. Novartis's pelacarsen and Novo Nordisk's IL-6 inhibitor showed no reduction in heart attacks or strokes. This evidence suggests skepticism toward technology promises, though specific causal links remain unproven.

Key points

• Two trials presented at the American Heart Association failed to show benefits for heart drugs despite genetic improvements.
• Novartis's pelacarsen and Novo Nordisk's IL-6 inhibitor showed no reduction in heart attacks or strokes.

Context

The evidence comes from two studies presented at the annual meeting of the American Heart Association in 2026. These trials highlight a pattern where new technologies fail to deliver promised outcomes, suggesting caution in technology hype.

Limitations

Evidence is limited to two studies presented at the American Heart Association in 2026. Specific causal links between genetic improvements and drug failures remain unproven.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 08/11/2026, 09:37:18 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiabf62my2o54js67vup4v6gbk3a3s54ma32yf75ng53asjho3bgdy